The newly cleared technology aims to standardize routine ultrasound examinations, reduce variability between operators, and minimize the need for repeat scans.
The approval strengthens Abbott’s position in the continuous glucose monitoring (CGM) market and expands its diagnostic capabilities beyond glucose-only tracking, which has traditionally defined wearable diabetes management tools.